Loading
Breast Cancer Treatment Studies / Advances in Oncology and Radiotherapy · Journal article
Cancers · September 4, 2026
Reinforces what was already believed, rather than introducing something new.
This large retrospective cohort study documents that South Asian American women with breast cancer present younger with more aggressive tumor subtypes and experience longer delays to treatment initiation, yet paradoxically achieve superior survival outcomes compared to non-Hispanic White women at 5, 10, and 15 years. The mechanism for this survival advantage remains unexplained and warrants further investigation into tumor biology and unmeasured clinical factors.
Retrospective cohort study. Women with breast cancer diagnosed 2004–2021 in the National Cancer Database, stratified as South Asian American or non-Hispanic White.. Intervention: South Asian American race/ethnicity. Compared with: Non-Hispanic White race/ethnicity. n = 2,363,627. United States (National Cancer Database).
SAAs represented 0.9% (20,561) of 2,363,627 patients in the cohort SAAs younger at diagnosis: 37.6% aged 20–49 vs. 20.6% of NHWs (p < 0.001) Time to first treatment longer for SAAs: 39.55 vs. 37.17 days (p < 0.001)
Surgical delays >60 days increased mortality by 59%; chemotherapy delays by 44%
Clinicians and researchers should recognize that SAA women with breast cancer present with distinct demographic and tumor biology profiles and experience disparities in treatment access and timing. The unexpected survival advantage despite treatment delays suggests unmeasured clinical or biological factors that warrant investigation to improve outcomes for all populations and understand the determinants of differential survival.
Large retrospective cohort study with robust sample size documenting disparities in breast cancer presentation and treatment patterns between ethnic groups, with clear survival outcomes but relying on observational data and administrative records rather than experimental evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should recognize that SAA women with breast cancer present with distinct demographic and tumor biology profiles and experience disparities in treatment access and timing. The unexpected survival advantage despite treatment delays suggests unmeasured clinical or biological factors that warrant investigation to improve outcomes for all populations and understand the determinants of differential survival.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: South Asian Americans (SAAs) represent the fastest-growing U.S. immigrant group but remain underrepresented in breast cancer research. This study utilizes the National Cancer Database (NCDB) to evaluate differences in tumor characteristics, treatment patterns, and survival outcomes between SAAs and non-Hispanic Whites (NHWs). Materials and Methods: A retrospective cohort analysis was conducted using NCDB data from 2004–2021. Women with breast cancer were stratified by race/ethnicity (SAA vs. NHW), and demographic, clinical, and treatment variables were compared. Outcomes assessed were overall survival (OS) and treatment delays, defined as initiation of surgery, chemotherapy, or radiation therapy > 60 days after diagnosis. Multivariable Cox proportional hazards models assessed OS. Results: Among 2,363,627 patients, 20,561 (0.9%) were SAAs and 2,343,066 (99.1%) NHWs. SAAs were younger at diagnosis, with 37.6% aged 20–49 vs. 20.6% of NHWs (p < 0.001). Insurance coverage differed, with SAAs more likely privately insured (63.0% vs. 54.2%, p < 0.001), less likely on Medicare (17.2% vs. 37.9%), and more often uninsured (4.5% vs. 1.2%). Time to first treatment was longer for SAAs (39.55 vs. 37.17 days, p < 0.001). Surgical delays >60 days increased mortality by 59%, while chemotherapy delays raised it by 44%. SAAs demonstrated higher survival at 5, 10, and 15 years (93%, 87%, 81%) vs. NHWs (87%, 76%, 64%). Median survival was 225.8 months but not estimable for SAAs. SAAs presented with aggressive subtypes: triple-negative and HER2-positive tumors. Conclusions: SAAs present younger with aggressive subtypes and treatment delays yet maintain survival advantages; reducing care barriers and clarifying tumor biology are vital to improving outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.